Two new drugs for chronic ITP

Medical Letter on Drugs and Therapeutics

Volumn 51, Issue 1305, 2009, Pages 10-11

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; ELTROMBOPAG; IMMUNOGLOBULIN; NPLATE; PLACEBO; ROMIPLOSTIM; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; CARRIER PROTEIN; FC RECEPTOR; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ABDOMINAL PAIN; CATARACT; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPEPSIA; ETHNICITY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INSOMNIA; LIVER FUNCTION TEST; MYALGIA; MYELOFIBROSIS; NAUSEA; PARESTHESIA; SHORT SURVEY; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; VOMITING; REVIEW;

BENZOIC ACIDS; CARRIER PROTEINS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDRAZINES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC;

EID: 60549104111     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. CL Erickson-Miller et al. Discovery and characterization of a selective nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005; 33:85.
2. B Wang et al. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76:628.
3. A Newland et al. An open-label unit dose-finding study of AMG 531, a novel thrombopoieis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135:547.
4. JB Bussel et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672.
5. DJ Kuter et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395.
6. C Newland et al. Evaluating the long-term efficacy of romiplostim (AMG-531) in patients with chronic immune thrombocytopenic purpura (ITP) during an open-label extension study Haematologica 2008; 93 (Suppl 1): 377. Abstract 0945.
7. JB Bussel et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357:2237.
8. J Bussel et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a phase III study. Haematologica 2007; 92(suppl 1): 143. Abstract 390.
9. JB Bussel et al. Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura. Blood 2008; 112(11):154. Abstract 3432.